Dental Practice & DSO Valuation Multiples: 2026 Benchmarks by Specialty and Size
By Dr. Hendrik Lai, Managing Partner, Viturtal Consulting
The short answer
In 2026, most published benchmarks put single-location dental practices at roughly 5x–8x adjusted EBITDA when sold to a DSO, multi-location groups at 8x–11x, and platform-scale groups with $5M+ of EBITDA at 10x–12x or higher [1][2][3]. Solo practices sold to another dentist are still usually priced on collections or seller's discretionary earnings (SDE), commonly 60%–85% of annual collections [4][5].
Those headline ranges hide more than they reveal. Four points matter more than any single number:
- Scale moves the multiple more than specialty. Going from one location to a small multi-site group is the biggest single jump in most published tiers [2][3].
- Specialty premiums are real but poorly measured. Every source agrees orthodontics and oral surgery trade above general dentistry. They disagree sharply on how far above (see the specialty section).
- The spread between good and average practices is widening. Headline multiples have held roughly steady for two years; what changed is dispersion, with premium practices still clearing the top of the range and average ones facing more friction [1].
- The multiple is not what you take home. Typical DSO deals pay 60%–85% in cash at close, with the rest in rollover equity and earnouts [6].
For how normalized EBITDA is built before any multiple is applied, see our Dental Practice Valuation: The Complete Guide.
2026 benchmarks by size and buyer type
The earnings figure the multiple applies to changes with the buyer. Individual dentists buying a solo practice usually price on collections or SDE, which includes the owner's full pay. DSOs and private equity price on adjusted EBITDA, which first deducts a market-rate salary for the treating dentist. Mixing the two bases is the most common reason owners misread their own number.
| Practice profile | Typical buyer | Earnings basis | Published 2026 range | Sources |
|---|---|---|---|---|
| Solo general practice | Individual dentist (often SBA-financed) | % of collections | 60%–85% of annual collections | [4][5] |
| Single-location practice, DSO add-on | Regional or national DSO | Adjusted EBITDA | 5x–8x | [2][3][8] |
| Under $1M EBITDA | Small DSO tuck-in | Adjusted EBITDA | 5x–7x | [2] |
| $1M–$3M EBITDA, multi-location | Regional DSO add-on | Adjusted EBITDA | 7x–9x | [2] |
| $3M–$5M EBITDA | Emerging platform | Adjusted EBITDA | 9x–11x | [2] |
| $5M+ EBITDA, platform-grade | PE sponsor or large DSO | Adjusted EBITDA | 10x–12x+ | [2][6] |
Two cautions on reading the table. First, the tiers come from sell-side advisers, not a public transaction database; dental deal multiples are almost never disclosed. Second, a practice moves within its band based on the drivers covered below, and those drivers can be worth more than the tier itself.
Why published multiples disagree
Search for "dental practice multiple" and you will find confident numbers that do not match. The table below lines up what several 2026 sources actually say. They agree on the shape of the market and disagree at the edges.
| Source (2026) | Single-location / add-on | Multi-location / platform | Specialty |
|---|---|---|---|
| FOCUS Investment Banking [8] | 5x–8x | 9x–11x platform | High demand for pediatrics, ortho, OMS, perio, endo; no separate range |
| The Sorso [2] | 5x–8x | 9x–11x regional; up to 12x at $5M+ | Ortho 7x–10x, OMS 6x–9x, pediatric 6x–8x (add-on) |
| Deal Prospectors [3] | 5x–8x | 8x–11x at $1M+ EBITDA | 10x–14x+ |
| McLerran & Associates [6] | 5x–8x | 10x–12x+ platform-grade | Premium over GP; OMS strongest demand |
| Sofer Advisors [10] | — | 6x–14x multi-location; 9x–12x for a clean 10-site group | — |
Three things drive the gaps:
- Different earnings bases. An SDE multiple and an EBITDA multiple on the same practice produce very different numbers, and some sources blend them.
- Different deal types. An add-on bought by an existing platform and a platform bought by a new sponsor are priced differently even at the same EBITDA.
- Seller-side incentives. Nearly every published range comes from a firm that earns fees when practices sell. That does not make the numbers wrong, but it favors the top of the range.
Our reading: treat the overlap as the working benchmark, and treat any single figure outside it, high or low, as a claim that needs a transaction behind it.
Multiples by specialty
Specialty practices generally trade above general dentistry at the same size, driven by higher per-procedure margins, referral-based revenue, and dedicated specialty DSO buyers [7]. Oral and maxillofacial surgery is most often named as attracting the strongest demand [6]. The size of the premium is where sources diverge.
| Specialty | Direction vs. general dentistry | Published EBITDA ranges (add-on / single site) | Collections-based range (private sale) | Main swing factors |
|---|---|---|---|---|
| General dentistry | Baseline | 5x–8x [2][3] | 65%–75% [9] | Hygiene share, provider concentration, payer mix |
| Orthodontics | Premium | 7x–10x [2] | 75%–90% [9] | Case starts, aligner competition, referral base |
| Oral & maxillofacial surgery | Premium; strongest demand [6] | 6x–9x [2] | 70%–85% [9] | Implant and full-arch volume, out-of-network revenue |
| Pediatric dentistry | Premium at multi-site scale | 6x–8x [2] | Varies by market [9] | Medicaid exposure caps the top of the range [2] |
| Periodontics | Modest premium, market-dependent [7] | Not separately published | 65%–80% [9] | Implant mix, buyer depth |
| Endodontics | Modest premium, market-dependent [7] | Not separately published | 60%–75% [9] | Referral concentration, buyer depth |
One source puts all specialties at 10x–14x+ EBITDA, a 20%–40% premium over general dentistry [3]. That figure reads as a platform-scale specialty number rather than a single-office one, and it sits well above the add-on ranges others publish. If you own a single-location specialty practice, plan around the lower ranges and treat the higher ones as what scale and competition can unlock.
Periodontics and endodontics have the thinnest data. Their buyer pools are smaller, and premiums depend on whether a specialty consolidator is actively building density in your market [7].
The collections rule of thumb, and when it fails
The oldest shortcut in dental transitions prices a general practice at a percentage of annual collections. Current 2026 sources place private sales at roughly 60%–85% of collections [5], with many general practices landing between 70% and 85% [4].
The shortcut works as a first screen for small practices sold to another dentist, because those buyers finance on cash flow and compare against similar offices. It breaks down as practices grow, because collections measure revenue, not profit [4]. Two offices collecting $1.5M can differ by hundreds of thousands of dollars in normalized earnings because of overhead, staffing, payer mix, and how the owner pays themselves.
A quick profitability check is the overhead benchmark buyers often use before full diligence: overhead near 50% of collections for a solo practice, 40% for a small group, and 30% for a mature platform [10]. A practice well above those levels will struggle to reach the top of any range, whichever method is used.
What moves the multiple
Buyers pay for EBITDA they believe will survive the sale. Two practices with identical EBITDA can land at very different multiples depending on how that EBITDA is built [1]. These are the levers with published, quantified effects.
| Driver | What buyers look for | Published effect | Sources |
|---|---|---|---|
| Scale | Multiple locations, $1M+ EBITDA | Moving from one location to three is described as roughly doubling the multiple | [2][3] |
| Owner dependence | Owner producing well under 90% of collections | 10%–20% valuation reduction when the owner produces 90%+ | [12] |
| Provider concentration | No single provider above 35%–40% of collections | 1x–2x EBITDA discount above that threshold | [3][10] |
| Hygiene | Hygiene above 30% of collections, strong recall | Supports top-of-band pricing | [2][7] |
| Payer mix | 60%+ fee-for-service or commercial PPO | Heavy Medicaid or HMO mix compresses 0.5x–1.0x; overall payer mix can move a practice 1–2 turns within its band | [6][11] |
| Management depth | A trained non-owner management team | Can add 1x–3x EBITDA in multi-location groups | [10] |
| Compliance | No open OSHA citations or payer audits | Unresolved issues can cut value 5%–20% | [10] |
Provider concentration deserves special attention in 2026. One adviser reports it moved from a secondary consideration to a primary reason DSOs walked away from deals in 2025 [3]. For owners two to three years from a sale, adding and retaining a producing associate is usually the highest-return preparation available.
Headline multiple vs. cash at close
A 9x offer and a 9x outcome are not the same thing. DSO transactions in 2026 commonly include 60%–85% cash at close, 10%–30% rollover equity, and earnouts running one to three years [6].
- Rollover equity is a reinvestment in the buyer. Its value depends on the platform's next sale, which is why the DSO restructurings covered below matter to sellers, not just lenders.
- Earnouts are usually tied to retained EBITDA or provider production. When owner dependence is high, buyers tend to shift value out of the headline and into the earnout [12].
- Employment terms for the selling dentist, often several years post-close, shape the real economics as much as price.
Compare offers on expected after-tax cash across several time horizons, with a realistic discount on rollover and earnout, rather than on the headline multiple alone.
The 2026 market behind the numbers
Demand for quality practices is strong, but 2026 has also exposed the limits of debt-funded consolidation. Both facts shape where multiples go next.
Capital is plentiful. Healthcare private equity set a record in 2025 with an estimated $191 billion in global deal value and 445 buyouts, the second-highest count on record [18]. Within dental, a 2026 buy-side survey found 69% of DSOs planning to increase acquisitions and 78% expecting a recapitalization within 12–36 months, with too few premium practices to go around [19].
Leverage has bitten. Lenders took control of Affordable Care, which supports about 425 practices, in a restructuring of its $1.4 billion credit structure expected to cut its debt by roughly 70% [15]. Dental Care Alliance followed with an out-of-court restructuring that shifted control to its lenders [16][20]. Lenders are now applying stricter underwriting to DSO capital requests [19].
Rates are moving the wrong way for buyers. On September 16, 2026, the Federal Reserve raised its target range by a quarter point to 3.75%–4.00%, its first increase since 2023 [17]. Most platform acquisitions are debt-financed, so higher borrowing costs pressure what leveraged buyers can pay. We would expect that pressure to show first in average-quality add-ons, not in premium practices where competition is thickest.
Consolidation is growing, not complete. The ADA Health Policy Institute reports 16.1% of US dentists were DSO-affiliated in 2024, more than double the 2015 share [13], and 27% of dentists less than ten years out of school [14]. Most dentists still own their practices, with ownership delayed rather than abandoned [21]. The supply of independent practices that DSOs want to buy is far from exhausted.
Worked example: one practice, three prices
Take an illustrative single-location general practice with $1.6M in annual collections. After normalizing owner pay to a market-rate dentist salary and removing personal expenses, it produces a 20% adjusted EBITDA margin, or $320,000. That margin sits inside the 18%–28% range one adviser cites for a healthy general practice after normalization [3].
| Scenario | Method | Headline value |
|---|---|---|
| Sale to an individual dentist | 70% of collections | $1.12M |
| DSO add-on, owner produces 90%+ of collections | 6x EBITDA, less a 15% concentration discount | about $1.63M |
| DSO add-on, associate in place, hygiene above 30% | 8x EBITDA | $2.56M |
The spread between the last two rows is roughly $930,000, and it comes from operations, not from the market. On a typical DSO structure, 60%–85% of the headline would be paid at close [6], so the owner should model the remainder as at-risk until the rollover is realized and the earnout is paid.
These figures illustrate the mechanics; they are not a valuation of any real practice.
Frequently asked questions
What EBITDA multiple does a dental practice sell for in 2026?
Most published 2026 benchmarks place single-location practices sold to DSOs at 5x–8x adjusted EBITDA, multi-location groups at 8x–11x, and platform-scale groups with $5M+ EBITDA at 10x–12x or higher [2][3][8]. Where a practice lands depends on provider concentration, hygiene strength, payer mix, and buyer competition.
What is the rule of thumb for valuing a dental practice?
For solo general practices sold to another dentist, the common rule of thumb is 60%–85% of annual collections [5]. It is a screening tool, not a valuation, because collections do not measure profit [4].
Do specialty dental practices sell for higher multiples?
Yes. Orthodontics, oral surgery, and pediatric practices generally command higher multiples than general dentistry at similar size [7], with oral surgery often cited as the strongest demand [6]. Published premiums vary widely, so single-office specialty owners should use conservative ranges.
What is the difference between SDE and EBITDA in a dental valuation?
SDE includes the owner's full compensation and is used when the buyer will work in the practice. Adjusted EBITDA deducts a market-rate salary for the treating dentist and is what DSOs and private equity buyers multiply. The same practice produces a much larger SDE than EBITDA, so the two multiples are not comparable.
How much does owner dependence reduce a dental practice's value?
Practices where the owner produces 90% or more of collections may see valuation reductions of about 10%–20% [12]. Separately, a single provider above 35%–40% of collections can draw a 1x–2x EBITDA discount [3][10].
How much of a DSO offer is paid in cash?
Typically 60%–85% at close, with 10%–30% as rollover equity and the rest in earnouts running one to three years [6].
Are dental practice multiples going up or down in 2026?
Headline ranges have been broadly stable, but dispersion is widening: premium practices still achieve top-of-range pricing while average practices face tougher diligence and structure [1]. Rising interest rates and 2026 DSO restructurings add pressure on leveraged buyers [15][17].
What percentage of dentists are affiliated with a DSO?
About 16.1% of US dentists were DSO-affiliated in 2024, per the ADA Health Policy Institute, more than double the 2015 share [13].
Next step
A multiple is only as good as the EBITDA it is applied to. Before comparing your practice to any range above, build a defensible normalized EBITDA; our Dental Practice Valuation: The Complete Guide walks through that process step by step.
This article is for general information only and is not a valuation, appraisal, or investment, legal, or tax advice. Ranges are drawn from the published sources below and vary by transaction.
References
All sources accessed September 28, 2026. Dental Transitions is the publishing site of McLerran & Associates.
- FOCUS Investment Banking. Dental Practice EBITDA Multiples 2026. April 2026.
- The Sorso. Dental Practice Valuation Multiples 2026: 5x–12x EBITDA. Reviewed April 2026.
- Deal Prospectors. Dental Practice Valuation: EBITDA Multiples by Size (2026). June 2026.
- McLerran & Associates. Pros and Cons of Selling a Dental Practice to a DSO. September 2026.
- GATP Solutions. Dental Practice Valuation: Methods, Multiples & 2026 Guide. 2026.
- McLerran & Associates. 2026 DSO Practice Multiples & EBITDA Valuation Guide. August 2026.
- McLerran & Associates. DSO Dental Practice Valuation Multiples: 2026 Guide. July 2026.
- FOCUS Investment Banking. Dental Practice EBITDA Multiples: 2026 Report. February 2026.
- Sofer Advisors. Dental Practice Valuation: Atlanta Owner's Guide 2026. March 2026. (Atlanta-market focus.)
- Sofer Advisors. How Multi-Location Dental Group Practices Are Valued in 2026. June 2026.
- McLerran & Associates. Dental Practice Sale Multiples: 2026 Valuation Guide. August 2026.
- Ad Astra Equity. Dental Practice Valuation & EBITDA Multiples (2026). June 2026. (Owner-dependence figure attributed there to Sofer Advisors.)
- American Dental Association, Health Policy Institute. The U.S. Dentist Workforce: 2025 Update. 2025.
- American Dental Association, Health Policy Institute. Practice Ownership Trends in Dentistry: A New Look at Old Data. 2025.
- Becker's Dental Review. Lenders to assume control of Affordable Care as part of restructuring deal. May 15, 2026.
- Dental Economics. Dental Care Alliance's restructuring signals a new era for DSOs. July 2026.
- Board of Governors of the Federal Reserve System. FOMC statement. September 16, 2026.
- Bain & Company. Global healthcare private equity hits record $190 billion deal value in 2025. January 8, 2026.
- Healthcare Growth Strategies. Dental M&A 2026: Ten Shifts DSO Leaders Must Understand Now. June 2026. (Summarizing TUSK Practice Sales survey data reported by Becker's Dental Review.)
- BriefGlance. Dental Care Alliance Sheds $1.1B Debt in Major Restructuring Deal. April 2026.
- DentistryIQ. Is dentistry really 35% consolidated? Let's check the math. August 8, 2026.